

## Isolation and identification of bacterial causes of clinical mastitis in cattle in Sulaimania region

S. A. Hussein

Department of Microbiology, College of Veterinary Medicine, University of Sulaimani, Sulaimania, Kurdistan Region, Iraq

(Received June 11, 2007; Accepted February 20, 2008 )

### Abstract

A total of 51 cases of bovine clinical mastitis in Sulaimani district were investigated for their bacteriological causative agents; 76 milk samples were cultured on primary and selective media and the isolated bacteria were tested for their susceptibility to antimicrobial agents used in commercial intramammary infusion products. Eighty two bacterial isolates were obtained and further identified using biochemical tests. *Escherichia coli* was the most common bacteria followed by *Staphylococcus aureus*, *Streptococcus agalactia* and coagulase-negative staphylococci. Two other bacterial species (*Pseudomonas aeruginosa* and *Streptococcus uberis*) were also isolated but in a lower proportion. Antibacterial susceptibility testing showed that the use of florfenicol, cephalexin and gentamicin may be useful for the treatment of clinical mastitis cases in cows.

**Keywords:** Bovine; Mastitis; Intramammary infection

### عزل وتشخيص المسببات الجرثومية لالتهاب الضرع السريري في الابقار في منطقة السليمانية

سهى علي حسين

فرع الأحياء المجهرية، كلية الطب البيطري، جامعة السليمانية، السليمانية، إقليم كردستان، العراق

### الخلاصة

أخذت عينات حليب من ٧٦ ربيع مصاب mastitic quarters وجدت في ٥١ بقرة تعاني من التهاب الضرع السريري clinical mastitis في منطقة السليمانية لأجل التحري عن المسببات الجرثومية لهذه الحالة. زرعت عينات الحليب على أوساط زرعيه جرثومية أوليه وأختياريه ومن ثم تم فحص حساسية الجراثيم المعزوله للمضادات الجرثومية التي تستخدم في الحقن التجاريه (commercial intramammary infusion products) المستخدمه للعلاج الموضعي لحالات التهاب الضرع. تم الحصول على ٨٢ عزله جرثومية وقد أظهرت الفحوصات الكيمياءحيويه أن أغلب هذه العزلات تعود لجراثيم الـ *Escherichia coli* تلتها جراثيم الـ *Staphylococcus aureus* و الـ *Streptococcus agalactia* و الـ Coagulase Negative Staphylococci. كما تم تشخيص نوعين آخرين من الجراثيم (الـ *Pseudomonas aeruginosa* و الـ *Streptococcus uberis*) ولكن بنسب أقل. أظهرت فحوصات حساسية الجراثيم المعزوله للمضادات الجرثومية ان الأستخدام المتزامن للفلوروفنيكول والسيفالكسين والجنتاميسين قد يكون نافعا لعلاج التهاب الضرع السريري في منطقة السليمانية.

## **Introduction**

Bovine mastitis is the most costly disease facing the dairy industry throughout the world. It creates estimated losses of about two billions dollars per year in the United States (1). The majority of losses is due to reduced milk production, production of lower quality milk, cost of drugs and veterinary services, increased culling rate and reduced reproductive efficiency (2).

Mastitis or intramammary infection can generally be classified as clinical and subclinical (3). Clinical mastitis is characterized by an abnormal secretion containing clots or flakes (4, 5). Sudden onset of clinical mastitis (acute clinical mastitis) is accompanied by swelling, hardness and increased temperature and it also may be accompanied by systemic signs such as loss of appetite, fever, dehydration, or depression (6).

No apparent changes in the udder or milk are expected with subclinical mastitis, although microorganisms can be isolated by appropriate culture techniques. Compositional changes and increased somatic cell count in milk usually accompany subclinical mastitis and can be detected by appropriate tests (3, 7).

Many of intramammary infections originate during the dry or nonlactating period and result in clinical or subclinical mastitis during early lactation (4). More than 135 different microorganisms have been isolated from bovine intramammary infections (3). The causative organisms of mastitis are categorized as contagious pathogens including *Staphylococcus aureus*, *Streptococcus agalactia*, and *Mycoplasma bovis* or as environmental pathogens such as environmental streptococci (e.g., *Streptococcus dysagalactia* and *Streptococcus uberis*), and the enterobacteriaceae (8-10). Coagulase-negative staphylococci, which colonize bovine teat skin and teat canals, are classed as skin flora opportunists (3).

Rapid reduction in herd mastitis level requires identification of infected glands and specific pathogens, followed by drug therapy and/or culling of affected cows. Thus, microbiological culturing is the single most reliable tool for developing a specific mastitis control program for a dairy herd (3, 11).

The objectives of this study were to isolate and identify mastitis associated bacteria in Sulaimani district and to determine the susceptibility of the isolated bacteria to antimicrobial agents used in commercial intramammary infusion products.

## **Materials and Methods**

### **Sample collection**

A total of 51 individual clinical cases of bovine mastitis were investigated from July 2003 through August 2006 at

the teaching veterinary hospital and at several small private cattle herds in Sulaimani district.

Milk samples were collected from 76 mastitic quarters which were recognized by swelling, hardness, warmth and/or abnormal secretions (abnormal color or consistency and/or presence of clots or flakes). Sampling of milk was performed according to Watts, (3) as below:

- The udder was carefully washed, dried and several streams of milk were forcibly stripped from the mastitic quarter. The teat of the affected quarter was then scrubbed with a cotton pledget soaked in 70% alcohol.
- Two streams of milk were collected into a sterile screw capped vials.
- Collected samples were immediately kept in an insulated container with ice packs and transferred to the laboratory for bacterial culturing.

### **Bacterial Isolation and identification**

Milk samples were brought to room temperature and mixed thoroughly. A 0.1 ml of each sample was surface plated on 5% calf blood agar, MacConkey's agar and nutrient agar.

The inoculated plates were subsequently incubated aerobically at 37°C and examined for growth after 16 to 48 hours of incubation.

Primary cultures were evaluated by visual examination of the morphology of the bacterial colonies and were subcultured on mannitol salt agar, eosin methylene blue agar and nutrient agar slants.

Identification of the purified bacterial cultures was applied using conventional bacteriological and biochemical procedures as described by Carter and Carter *et al.* (12 and 13) as well as commercial identification kits including the enterosystem 18R (Liofilchem s.r.l., Italy) and the Analytic Profile Index -API- (Biomériux, France).

Cultures were considered to be negative when no bacterial growth was observed on the culture plates and they were considered to be positive when only one or two species of bacteria, known to cause mastitis, were isolated from a sample or when contagious pathogens such as *Staphylococcus aureus* or *Streptococcus agalactia* were recovered, even in a mixture of environmental bacteria. On the other hand, cultures were considered to be contaminated when they show mixed growth of three or more environmental bacteria (11).

### **Susceptibility testing**

The Bauer Kirby procedure (14), on Muller-Hinton agar plates was used to determine the susceptibility of the bacterial isolates that obtained in the present study to antimicrobial agents used in commercial intramammary infusion products such as ampicillin, cephalixin,

erythromycin, florfenicol, gentamicin, penicillin, streptomycin, and tetracycline.

Following 16-18 hours of aerobic incubation, the plates were examined and the diameter of the zone of inhibition was measured by a ruler. The zone diameters were expressed as resistant, intermediate or susceptible according to Chengappa (15).

## Results and Discussion

The identification of etiological agents of mastitis along with their susceptibility or resistance to antimicrobial agents used in intramammary infusion products, may help in controlling bovine mastitis, one of the most costly diseases affecting the dairy industry, and in developing therapy protocols for particular dairy farms (11). To our knowledge, this is the first investigation of clinical mastitis cases in cattles in Sulaimani district.

Of the seventy six milk samples examined in the present study, six samples revealed negative cultures and eleven samples revealed mixed cultures of three or more environmental bacteria and accordingly considered contaminated. The remaining 59 samples revealed positive cultures of which, 23 samples showed dual bacterial isolation, i. e., a total of 82 different bacterial isolates were recovered and the biochemical tests revealed these isolates belong to 7 species. The isolation frequency of the bacterial strains and their responses to the most important biochemical tests are summarized in table 1 and 2 respectively.

The high prevalence of *Escherichia coli*-induced clinical mastitis encountered in the present study is in agreement with the findings of other authors (16-18) who considered the *Escherichia coli* organisms as major etiological agents of clinical mastitis. They are opportunistic environmental or enteric pathogens and it may be possible for the infected quarter to serve as reservoir for recurrent episodes of *Escherichia coli*-induced clinical mastitis (19,20). It is worth mentioning that cases of *Escherichia coli*-induced clinical mastitis are often of very short duration and milk samples may reveal negative cultures in approximately 20% of such cases (11,16), accordingly, the six culture-negative milk samples encountered in the present study may be attributed either to *Escherichia coli* or to other intramammary pathogens could not be detected in the present study such as *Mycoplasma* species.

*Staphylococcus aureus* and *Streptococcus agalactia*-induced clinical mastitis cases were also encountered in a high prevalence in this study. This finding is similar to those of other authors (4, 21,22). However, it disagrees with findings of some other authors (6,23) who mentioned that these two bacteria are currently classified as causes of subclinical rather than clinical mastitis. This disagreement

can be attributed to the poor mastitis control measures applied in Sulaimani district wherein, cattle breeding is of the semi-intensive type and management of animals is the whole family duty especially females who have little or even no idea about the principle concepts of animal management compared to the effective control measures followed in dairy herds of the developed countries. Nevertheless *Staphylococcus aureus* and *Streptococcus agalactia* are considered significant organisms associated with clinical and subclinical bovine mastitis worldwide (9, 10, 13 and 24) due to persistent cow –to– cow spread, possibly via milking machines and perhaps by the hands of milkers (25). Their main reservoirs are infected quarters (3, 26). In addition, *Staphylococcus aureus* can also be isolated from the skin of the udder and teats and from many other sites in dairy cows as well as feed and caretakers (27, 28).

The other bacterial species frequently isolated in the present study are coagulase-negative staphylococci including *Staphylococcus epidermidis* and *Staphylococcus xylosum*. The importance of such bacterial species as a cause of clinical mastitis has come under increased scrutiny in dairy herds used effective recommended mastitis control measures, they were previously considered as mastitis minor pathogens associated with a mild inflammatory reaction but they are now known to cause clinical mastitis (29, 30). They colonize bovine teat skin and teat canals, thus they are classed as skin flora opportunists (3).

Other bacteria including *Pseudomonas aeruginosa* and *Streptococcus uberis* were also isolated from mastitic quarters milk but in a lower proportion compared with those mentioned above (table 1). These findings are generally in agreement with those reported by other authors (4, 21, 22).

The natural habitat of *Pseudomonas aeruginosa* organisms is water, soil, and decaying vegetation; they also may be found on the skin and mucous membranes, and in feces, thus they are classified as environmental mammary gland pathogens (13).

*Streptococcus uberis* is classified as an environmental mammary gland pathogen; it colonizes various body sites including teat canal and has been isolated from bedding material. (3).

The susceptibility of the bacterial species isolated in the present study to the antimicrobial agents used in commercial intramammary infusion products is shown in table 3. These results are generally in agreement with the findings of other authors (3, 11, 13, 31). They showed that except *Pseudomonas aeruginosa*, all bacterial isolates obtained in the present study were susceptible or at least intermediately susceptible to florfenicol and cephalixin. In addition, the *Escherichia coli* isolates were also susceptible or intermediately susceptible to ampicillin, gentamicin and streptomycin; the *Staphylococcus* isolates were intermediately susceptible to erythromycin, gentamicin, and

streptomycin; and the streptococcal isolates showed high susceptibility to penicillin G, ampicillin, and erythromycin. Regarding the *Pseudomonas aeruginosa* isolates, they were resistant to most antibacterial agents; however they

showed moderate susceptibility to gentamicin. Thus, the simultaneous use of florfenicol, cephalixin and gentamicin may be useful for the treatment of bovine clinical mastitis cases in Sulaimani district.

Table 1: Bacterial isolates from milk samples obtained from the mastitic quarters.

Bacteria	Number of isolates	%*
<i>Escherichia coli</i>	31	37.8
<i>Staphylococcus aureus</i>	19	23.2
<i>Streptococcus agalactia</i>	15	18.3
<i>Staphylococcus epidermidis</i>	9	10.98
<i>Staphylococcus xylosum</i>	3	3.66
<i>Pseudomonas aeruginosa</i>	3	3.7
<i>Streptococcus uberis</i>	2	2.4
Total	82	

\* The percentage is with respect to the total number of isolates (82).

Table 2: The biochemical properties of the bacterial isolates obtained from milk samples of mastitic quarters.

Bacteria	Indole production	Methyl red	Voges - proscauer	Citrate utilization	Hydrogen sulfide (TSI)	Oxidase	Coagulase	Catalase	Hemolysis	Nitrate reduction	Arginine dihydrolase	Ornithin decarboxylase	Lysine decarboxylase	Lactose	Maltose	Mannitol	Xylose	Gelatin hydrolysis	Esculin hydrolysis
<i>Escherichia coli</i>	+	+	-	-	-	*			$\alpha, \beta$	-	V	V	+	+	+		-	V	
<i>Staphylococcus aureus</i>						-	+	+	$\beta$	+	-	-	+	+	+				
<i>Streptococcus agalactia</i>						-	-	-	$\alpha, \beta$				+	+	-			-	
<i>Staphylococcus epidermidis</i>						-	-	+	-	+	-	-	+	+	-				
<i>Staphylococcus xylosum</i>						-	-	+	-	+	-	-	+	+	+	+	+	+	
<i>Pseudomonas aeruginosa</i>	-				-	+			$\beta$	+	+	-	-	-	-			+	
<i>Streptococcus uberis</i>						-	-	-	$\alpha$				+	+	+			+	

\* : not tested; V: Variable

Table 3: Antimicrobial susceptibility testing of the bacterial isolates obtained in the present study to the antimicrobial agents used in commercial intramammary infusion product.

Antimicrobial agent	Disk potency	Inhibition zone diameter *					
		Resistant		Intermediate		Susceptible	
		Diameter " mm "	No. of isolates	Diameter " mm "	No. of isolates	Diameter " mm "	No. of isolates
<b>Ampicillin</b>							
<i>Escherichia coli</i>	10 µg	≤ 11	2	12 – 13	7	≥ 14	22
<i>Staphylococcus aureus</i>	10 µg	≤ 28	19	— **	—	≥ 29	—
<i>Streptococcus agalactia</i>	10 µg	≤ 21	—	— **	—	≥ 30	15
<b>Cephalexin</b>							
<i>Escherichia coli</i>	30 µg	≤ 14	5	15 – 17	14	≥ 18	12
<i>Staphylococcus aureus</i>	30 µg	≤ 14	—	15 – 17	5	≥ 18	14
<i>Streptococcus agalactia</i>	30 µg	≤ 14	—	15 – 17	2	≥ 18	13
<b>Erythromycin</b>							
<i>Escherichia coli</i>	15 µg	≤ 13	28	14 – 17	3	≥ 18	—
<i>Staphylococcus aureus</i>	15 µg	≤ 13	4	14 – 17	9	≥ 18	6
<i>Streptococcus agalactia</i>	15 µg	≤ 13	—	14 – 17	5	≥ 18	10
<b>Florfenicol</b>							
<i>Escherichia coli</i>	30 µg	≤ 12	—	13 – 17	10	≥ 18	21
<i>Staphylococcus aureus</i>	30 µg	≤ 12	2	13 – 17	5	≥ 18	12
<i>Streptococcus agalactia</i>	30 µg	≤ 12	3	13 – 17	5	≥ 18	7
<b>Gentamicin</b>							
<i>Escherichia coli</i>	10 µg	≤ 12	4	13 – 14	9	≥ 15	18
<i>Staphylococcus aureus</i>	10 µg	≤ 12	3	13 – 14	8	≥ 15	8
<i>Streptococcus agalactia</i>	10 µg	≤ 12	15	13 – 14	—	≥ 15	—
<b>Penicillin G ***</b>							
<i>Escherichia coli</i>	10 U	≤ 11	28	12 – 21	3	≥ 22	—
<i>Staphylococcus aureus</i>	10 U	≤ 20	16	21 – 28	3	≥ 29	—
<i>Streptococcus agalactia</i>	10 U	≤ 11	—	12 – 21	—	≥ 22	15
<b>Streptomycin</b>							
<i>Escherichia coli</i>	10 µg	≤ 11	7	12 – 14	13	≥ 15	11
<i>Staphylococcus aureus</i>	10 µg	≤ 11	5	12 – 14	8	≥ 15	6
<i>Streptococcus agalactia</i>	10 µg	≤ 11	15	12 – 14	—	≥ 15	—
<b>Tetracycline</b>							
<i>Escherichia coli</i>	30 µg	≤ 14	26	15 – 18	5	≥ 19	—
<i>Staphylococcus aureus</i>	30 µg	≤ 14	17	15 – 18	2	≥ 19	—
<i>Streptococcus agalactia</i>	30 µg	≤ 14	3	15 – 18	7	≥ 19	5

\* The interpretive standards of the inhibition zone diameter in this table are mentioned according to Chengappa, 1990 (15).

\*\* Not available or not recommended.

\*\*\* Benzyl-penicillin.

Table 3. (continued)

Antimicrobial agent	Disk potency	Inhibition zone diameter *					
		Resistant		Intermediate		Susceptible	
		Diameter " mm "	No. of isolates	Diameter " mm "	No. of isolates	Diameter " mm "	No. of isolates
Ampicillin							
Coagulase – negative staphylococci	10 µg	≤ 28	9	— **	—	≥ 29	3
<i>Pseudomonas aeruginosa</i>	10 µg	≤ 11	3	12 – 13	—	≥ 14	—
<i>Streptococcus uberis</i>	10 µg	≤ 21	—	— **	—	≥ 30	2
Cephalexin							
Coagulase – negative staphylococci	30 µg	≤ 14	—	15 – 17	4	≥ 18	8
<i>Pseudomonas aeruginosa</i>	30 µg	≤ 14	3	15 – 17	—	≥ 18	—
<i>Streptococcus uberis</i>	30 µg	≤ 14	—	15 – 17	—	≥ 18	2
Erythromycin							
Coagulase – negative staphylococci	15 µg	≤ 13	4	14 – 17	3	≥ 18	5
<i>Pseudomonas aeruginosa</i>	15 µg	≤ 13	3	14 – 17	—	≥ 18	—
<i>Streptococcus uberis</i>	15 µg	≤ 13	—	14 – 17	—	≥ 18	2
Florfenicol							
Coagulase – negative staphylococci	30 µg	≤ 12	—	13 – 17	2	≥ 18	10
<i>Pseudomonas aeruginosa</i>	30 µg	≤ 12	3	13 – 17	—	≥ 18	—
<i>Streptococcus uberis</i>	30 µg	≤ 12	—	13 – 17	—	≥ 18	2
Gentamicin							
Coagulase – negative staphylococci	10 µg	≤ 12	1	13 – 14	8	≥ 15	3
<i>Pseudomonas aeruginosa</i>	10 µg	≤ 12	—	13 – 14	3	≥ 15	—
<i>Streptococcus uberis</i>	10 µg	≤ 12	2	13 – 14	—	≥ 15	—
Penicillin G ***							
Coagulase – negative staphylococci	10 U	≤ 20	9	21 – 28	—	≥ 29	3
<i>Pseudomonas aeruginosa</i>	10 U	≤ 11	3	12 – 21	—	≥ 22	—
<i>Streptococcus uberis</i>	10 U	≤ 11	—	12 – 21	—	≥ 22	2
Streptomycin							
Coagulase – negative staphylococci	10 µg	≤ 11	3	12 – 14	5	≥ 15	4
<i>Pseudomonas aeruginosa</i>	10 µg	≤ 11	1	12 – 14	2	≥ 15	—
<i>Streptococcus uberis</i>	10 µg	≤ 11	2	12 – 14	—	≥ 15	—
Tetracycline							
Coagulase – negative staphylococci	30 µg	≤ 14	8	15 – 18	1	≥ 19	3
<i>Pseudomonas aeruginosa</i>	30 µg	≤ 14	3	15 – 18	—	≥ 19	—
<i>Streptococcus uberis</i>	30 µg	≤ 14	—	15 – 18	1	≥ 19	1

\* The interpretive standards of the inhibition zone diameter in this table are mentioned according to Chengappa, 1990 (15).

\*\* Not available or not recommended.

\*\*\* Benzyl-penicillin.

## References

1. DeGraves FJ, Fetrow F. Economics of mastitis and mastitis control. *The Veterinary Clinics of North America (Food Animal Practice)* 1993; 9: 421-434.
2. Barker AR, Schrick FN, Lewis MJ, Dowlen HH, Oliver SP. Influence of clinical mastitis during early lactation on reproductive performance of Jersey cows. *J. Dairy Sci.* 1998; 81: 1285-1290.
3. Watts JL. Bovine mastitis. In: Carter, G.R.; Cole, Jr., J.R. (Eds.). *Diagnostic Procedures in Veterinary Bacteriology and Mycology*. 5th edition Academic Press, Inc., SanDiego, California 1990.
4. Bartlett PP, Miller GY, Lance SE, Lawrance EH. Clinical mastitis and intramammary infection on Ohio dairy farms. *Prev. Vet. Med.* 1992; 12: 59-71.
5. Hortet P, Seegers H. Loss in milk yield and related composition changes resulting from clinical mastitis in dairy cows. *Prev. Vet. Med.* 1998; 37: 1 – 20.
6. Hillerton JE, Bramley AJ, Staker RT, McKinnon CH. Patterns of intramammary infection and clinical mastitis over a 5 year period in a closely monitored herd applying mastitis control measure. *J Dairy Res.* 1995; 62: 39 – 50.
7. Holdaway RJ, Holmes CW, Steffert JJ. A comparison of indirect methods for diagnosis of subclinical intramammary infection in lactating dairy cows. *Aust. J. Dairy Tech.* 1996; 51: 64 -71.
8. Hogan JS, Smith KL. A practical look at environmental mastitis. *Comp. Continuing Educ. Pract. Vet.* 1987; 9: 341-344.
9. Watts JL. Etiological agents of bovine mastitis. *Vet. Microbiol.* 1988; 16: 41-66.
10. Bramley AJ. Mastitis. In: Andrews AH, Blowey RW, Boyd H, Eddy RG. (Eds.). *Bovine Medicine: Diseases and Husbandry of cattle*. Blackwell Scientific Publication, Boston 1992.
11. Sears PM, Gonzalez RN, Wilson DJ, Han HR. Procedures for mastitis diagnosis and control. *The Veterinary Clinics of North America (Food Animal Practice)* 1993; 9: 445-468.
12. Carter GR. Isolation and Identification of Bacteria from Clinical Specimens. In: Carter GR, Cole JR. (Eds.) *Diagnostic Procedures in Veterinary Bacteriology and Mycology*. 5th edition, Academic Press Inc., San Diego, California 1990.
13. Carter GR, Chengappa MM, Roberts AW. *Essentials of Veterinary Microbiology*. 5th edition, Williams & Wilkins, Baltimore, Philadelphia 1995.
14. Bauer AW, Kirby WMM, Sherri JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. *Am. J. Clin. Pathol.* 1966; 45: 493-496.
15. Chengappa MM. Antimicrobial Agents and Susceptibility Testing. In Carter GR, Cole JR. (Eds.) *Diagnostic Procedures in Veterinary Bacteriology and Mycology*. 5th edition, Academic Press Inc., San Diego, California 1990.
16. Gonzalez RN, Jasper DE, Kronlund NC, Farver TB, Cullor JS, Bushnell RB, Dellinger JD. Clinical mastitis in two California dairy herds participating in contagious mastitis control programs. *J. Dairy Sci.* 1990; 73: 648-660.
17. Miltenburg JD, Delange D, Crauwels APP, Bongers JH, Tielen MJM, Schukken YH, Elbers ARW. Incidence of clinical mastitis in a random sample of dairy herds in the Southern Netherlands. *Vet. Rec.* 1996; 139: 204-207.
18. Döpfer D, Barkema HW, Lam GM, Schukken YH, Gaastra W. Recurrent clinical mastitis caused by *Escherichia coli* in dairy cows. *J. Dairy Sci.* 1999; 82: 80-85.
19. Nemeth J, Muckle CA, Gyles CL. In vitro comparison of bovine mastitis and fecal *Escherichia coli* isolates. *Vet. Microbiol.* 1994; 40: 231-238.
20. Döpfer D, Almeida RA, Lam GM, Nederbragt H, Oliver SP, Gaastra W. Adhesion and invasion of *Escherichia coli* from single and recurrent clinical cases of bovine mastitis in vitro. *Vet. Microbiol.* 2000; 74: 331-343.
21. Dinsmore RP, English PB, Gonzalez RN, Sears PM. Use of augmented cultural techniques in the diagnosis of the bacterial cause of clinical bovine mastitis. *J. Dairy Sci.* 1992; 75: 2706-2712.
22. Lafı SQ, Al-Rawasheh OF, Ereifej KI, Hailat NQ. Incidence of clinical mastitis and prevalence of subclinical udder infections in Jordanian dairy cattle. *Prev. Vet. Med.* 1994; 18: 89-98.
23. Sargeant JM, Scott HM, Leslie KE, Ireland MJ, Bashir A. Clinical mastitis in dairy cattle in Ontario: Frequency of occurrence and bacteriological isolates. *Can. Vet. J.* (1998). 39: 33-38.
24. Su C, Kanevsky I, Jayarao BM, Sordillo LM. Phylogenetic relationships of *Staphylococcus aureus* from bovine mastitis based on coagulase gene polymorphism. *Vet. Microbiol.* 2000; 71: 53-58.
25. Myllys V, Ridell J, Bjorkroth Biese I, Pyorala SHK. Persistence in bovine mastitis of *Staphylococcus aureus* clones as assessed by random amplified polymorphic DNA analysis, ribotyping and biotyping. *Vet. Microbiol.* 1997; 51: 245-251.
26. Rivas AL, Gonzales RN, Wiedmann M, Bruce JL, Cole EM, Bennett GJ, Schulte HF, Wilson DJ, Mohammed HO, Batt CA. Diversity of *Streptococcus agalactia* and *Staphylococcus aureus* ribotypes recovered from New York dairy herds. *Am. J. Vet. Res.* 1997; 58: 482-487.
27. Roberson JR, Fox LK, Hancock DD, Gay JM, Besser TE. Sources of intramammary infection from *Staphylococcus aureus* in dairy heifers at first parturition. *J. Dairy Sci.* 1998; 81: 687-693.
28. Larsen HD, Sloth KH, Elsberg C, Enevoldson C, Pedersen LH, Eriksen NHR, Aarestrup FM, Jensen NE. The dynamics of *Staphylococcus aureus* intramammary infection in nine Danish dairy herds. *Vet. Microbiol.* 2000; 71: 89-101.
29. Harmon RJ, Langlois BE. Mastitis due to coagulase-negative *Staphylococcus* species. *Agri-Pract.* 1989; 10: 29-34.
30. Bes M, Guérin-Faubleé V, Meugnier H, Etienne J, Freney J. Improvement of the identification of staphylococci isolated from bovine mammary infection using molecular methods. *Vet. Microbiol.* 2000; 71: 287- 294.
31. Erskine RS, Bartlette PC, Vanlenta J. Efficacy of systemic cetifur as a therapy for severe clinical mastitis in dairy cattle. *J. Dairy Sci.* 2002; 85: 2571-2575.